Compounds for treatment of fluoroquinolone-resistant bacteria

Joseph S Bair (Inventor), Paul J Hergenrother (Inventor), Elizabeth I Parkinson (Inventor)

Research output: Patent


Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.
Original languageEnglish (US)
U.S. patent number9920069
StatePublished - Mar 20 2018


Dive into the research topics of 'Compounds for treatment of fluoroquinolone-resistant bacteria'. Together they form a unique fingerprint.

Cite this